Biopharma companies make big bets and investments in every single drug candidate that enters the drug development process. Yet, making difficult strategic decisions on which trials to pursue, how to design trials (e.g. head-to-head; which drug candidate;...

Selecting the right solution from the vast AI landscape & dive into the inner workings of applying causal AI to pharma R&D In this 30-minute webinar, the GNS Healthcare team introduces you to the complex landscape of AI and help you hone in on one specific...

This year’s State of Possible Conference, MassBio's Annual Meeting, will celebrate what’s possible in our industry and for patients today that wasn’t five or 10 years ago. The two-day event will draw over 600 industry leaders from Massachusetts and beyond to debate...

Artificial Intelligence (AI) and Machine Learning (ML) are rapidly transforming industries, from autonomous cars, to logistics, to technology – and now biotechnology. Excitement about AI and ML driven solutions for accelerated drug discovery, drug development, and...

The future of medicine is data-driven and AI-enabled. Artificial intelligence will impact diagnosis, treatment decisions and patient care. Learn from others along the value-chain to understand how to effectively translate technology, data and analytic innovations into...

Biopharma companies have long struggled to identify the best responders for specific drugs.  Fortunately, data availability and technological advancements are now advanced enough for machine learning to help predict patient response using causal AI. The implications...

Colin Hill, CEO and Co-founder of GNS Healthcare, joined distinguished speakers at the Milken Institute Global Conference to discuss the impact of AI and machine learning on cancer medicine, including: Mike Nohaile, Senior Vice President of Strategy, Commercialization...